Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Drug M&As Seen Continuing For Three Years Until MNCs Dominate

This article was originally published in PharmAsia News

Executive Summary

Merger and acquisition fever in India is expected to continue for another two or three years, leading eventually to multinational drug makers having more clout than domestic firms. Analysts and pharma experts believe the MNCs will gain strength vis-à-vis domestic makers on a steady basis until the shift of dominance begins in another three years. M&A activity among Indian drug makers has grown since the first one, the 2006 acquisition of Matrix Laboratories by U.S.-based Mylan Laboratories. Currently, Indian firms still dominate, with 75 percent of the local market share, but analysts see that percentage slowly decreasing. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts